pfs230d1m-epa/alhydrogel

Vaccineexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Dec 10, 2014 (NCT02334462)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • pfs230d1m-epa/alhydrogel

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02334462Phase 1Dec 10, 2014Charles Mérieux Center for Infectious Disease, Mali, National Institute of Allergy and Infectious Diseases (NIAID)
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Charles Mérieux Center for Infectious Disease, MaliAcademic/Hospital1012014
National Institute of Allergy and Infectious Diseases (NIAID)Government1112014
2 organizations
Page 1 / 1